Anti-Obinutuzumab Polyclonal Antibody
Product Specifications
Background
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Host
Rabbit
Immunogen
Obinutuzumab
Target
Rabbit polyclonal to Gazyva.
Clonality
Polyclonal
Applications
ELISA
Purification
Purified by antigen affinity column.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Storage Conditions
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Notes
Antibodysystem can customize this product per customer's request including product size, buffer components, etc. For research use only.
Specificity
The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Isotype
IgG
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
